21028 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
ENGINEERING OF DNASE ENZYMES FOR MANUFACTURING AND THERAPY
#2COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#3COMPOSITIONS AND METHODS COMPRISING PROGRAMMABLE SNRNAS FOR RNA EDITING
#4COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#5COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#6ANTIMICROBIAL FEED ADDITIVE
#7HYBRID AAV VECTOR ENHANCING TRANSGENE EXPRESSION IN THE LIVER
#8Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses
#9Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies
#10PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF
#11INJECTION COMPOSITION FOR LIPOLYSIS
#12AAV-IDUA VECTOR FOR TREATMENT OF MPS I
#13CLINICALLY PROVEN SUBCUTANEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND THEIR USES IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE
#14AAV PARTICLES COMPRISING LIVER-TROPIC CAPSID PROTEIN AND ACID ALPHA-GLUCOSIDASE AND USE TO TREAT POMPE DISEASE
#15INGESTIBLE IN VIVO-ASSEMBLING DRUG RELEASE FORMULATIONS AND METHODS
#16POLYNUCLEOTIDES
#17Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
#18IONIZABLE CATIONIC LIPIDS
#19COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MILK THISTLE EXTRACT OR POWDER
#20METHODS FOR TREATING FARBER DISEASE
#21POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#22Hyaluronidase Enzyme Formulations for High Volume Administration
#23COMPOUNDS, DEVICES, AND USES THEREOF
#24ANTIBODIES THAT BIND OX40L IN COMBINATION WITH HYALURONIDASE OR A VARIANT THEREOF
#25Uses of Dendrobium polysaccharides and vancomycin-sensitive bacteria, and compositions containing the same
#26DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF
#27Antibody Compositions and Methods of Use Thereof
#28CELL WALL HYDROLASES TARGETING C. ACNES
#29High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease
#30SULFORAPHANE SUPPLEMENT IN GUMMY FORM
#31SIALYLATED GLYCOPROTEIN COMPOSITION AND USES THEREOF
#32AGENT FOR IMPROVING INTESTINAL FLORA
#33METHODS FOR PROMOTING NERVE GROWTH
#34COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES
#35METHODS OF TREATING BEHAVIORAL SYMPTOMS OF NEUROLOGICAL AND MENTAL DISORDERS
#36Combination treatment for atopic dermatitis
#37COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES
#38Implantable Device for Sustained Release of a Macromolecular Drug Compound
#39METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES
#40GENE THERAPY
#41Methods for Treating Pompe Disease
#42PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND PH20 VARIANTS OR FRAGMENTS THEREOF
#43METHODS OF TREATING TUMORS
#44PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND rHuPH20 OR VARIANTS OR FRAGMENTS THEREOF
#45COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASES
#46METHODS FOR THE TREATMENT OF SYMPTOMS OF NEUROLOGICAL AND MENTAL HEALTH DISORDERS
#47Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#48Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses
#49SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
#50TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF
#51COACTIVE COMBINATIONS OF ANTIMICROBIALS WITH DISPERSINB
#52Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
#53Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
#54MUTANASES AND ORAL CARE COMPOSITIONS COMPRISING SAME
#55CNS DELIVERY OF THERAPEUTIC AGENTS
#56HYALURONIDASE HYAL1 VARIANT EXHIBITING ACTIVITY IN NEUTRAL PH
#57BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOF
#58ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
#59METHODS FOR ENHANCING ADOPTIVE CELL TRANSFER IMMUNOTHERAPIES
#60PROBIOTIC COMPOSITION TO REDUCE PATHOGENESIS IN POULTRY AND METHODS FOR USE THEREOF
#61COMPOSITION CONTAINING DIGESTIVE ENZYMES AND NUTRIENTS SUITABLE FOR ENTERAL ADMINISTRATION
#62COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE
#63FEED ADDITIVE COMPRISING ENZYME COMBINATIONS
#64Hyaluronidase Enzyme Formulations for High Volume Administration
#65COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTINOMYCETIA INFECTIONS
#66COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES
#67ENGINEERING B CELL-BASED PROTEIN FACTORIES TO TREAT SERIOUS DISEASES
#68P2RY2 ACTIVITY MODULATORS
#69METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE
#70Tissue Modifier And Uses Therefor
#71FREEZE DRIED COMPOSITIONS
#72Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses
#73LIQUID COMPOSITIONS
#74OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF
#75Animal Feed Composition and Uses Thereof
#76Controlled-Release and Stratified Cyclodextrin Inclusion Complex Vehicles
#77LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USE
#78PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME
#79COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTINOMYCETIA INFECTIONS
#80IDURONIDASE STABILIZERS AND USES THEREOF
#81Disulfide Bond Stabilized Polypeptide Compositions And Methods Of Use
#82METHODS AND COMPOSITIONS FOR USING PLASMA CELL DEPLETING AGENTS AND/OR B CELL DEPLETING AGENTS TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE AND ENABLE AAV TRANSDUCTION AND RE-DOSING
#83COMPOSITIONS AND METHODS FOR TREATING METACHROMATIC LEUKODYSTROPHY DISEASE AND RELATED DISORDERS
#84HOMOVANILLYL ALCOHOL (HVA), HVA ISOMER, METHODS OF MAKING COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS USING SUCH COMPOUNDS
#85MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONS
#86THERAPEUTIC ADENO-ASSOCIATED VIRUS USING CODON OPTIMIZED NUCLEIC ACID ENCODING ALPHA-GLUCOSIDASE (GAA) FOR TREATING POMPE DISEASE, WITH SIGNAL PEPTIDE MODIFICATIONS
#87COMPOSITIONS COMPRISING A MUSCLE ACTIVE PROMOTER AND METHODS OF USING THE SAME
#88Antibody Compositions and Methods of Use Thereof
#89RECOMBINANT TMEM2 EXTRACELLULAR DOMAIN AND USES THEREOF
#90ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES
#91PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#92PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#93PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#94PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#95PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#96HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS
#97COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
#98COMPOSITIONS AND METHODS FOR PROMOTING A HEALTHY MICROBIAL FLORA IN A MAMMAL
#99METHODS AND COMPOSITIONS FOR INCREASING GALACTOSIDASE BETA-1 ACTIVITY IN THE CNS
#100PEPTIDE REGULATORS OF METABOLISM
#101SUPPLEMENT COMPOSITION FOR CONSUMPTION BY INDIVIDUALS BEING ADMINISTERED A GLP-1 AGONIST
#102METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
#103COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
#104USE OF LENTIVECTOR-TRANSDUCED T-RAPA CELLS FOR AMELIORATION OF LYSOSOMAL STORAGE DISORDERS
#105ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF
#106THERAPEUTIC ADENO-ASSOCIATED VIRUS FOR TREATING POMPE DISEASE WITH LONG TERM CESSATION OF GAA ENZYME REPLACEMENT THERAPY
#107POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF
#108IONIZABLE CATIONIC LIPIDS
#109METHODS AND COMPOSITIONS FOR IMPROVED COGNITION
#110METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A
#111COMPOSITIONS FOR GUT HEALTH
#112METHODS FOR TREATING INHERITED METABOLIC DISORDERS
#113Lyophilized Pharmaceutical Compositions Comprising A Lipid Nanoparticle
#114LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A
#115ORAL CARE COMPOSITION COMPRISING ENZYMES
#116PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#117METHODS OF TREATING GAUCHER DISEASE AND GBA-PARKINSON’S DISEASE
#118METHODS OF TREATING NEURODEGENERATIVE DISORDERS
#119Lipid Nanoparticle Compositions and Methods for mRNA Delivery
#120COMPOSITIONS COMPRISING GLUCOCEREBROCIDASE AND METHODS OF USE THEREOF
#121PROTEOLYTIC ENZYME COMPOSITION
#122COMPOSITIONS AND METHODS FOR EXTRACTING COMPOUNDS
#123COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE CELL FUNCTION USING MODIFIED CELLS WITH GLYCOCALYX EDITING ENZYMES
#124METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE
#125COMBINATION OF HYDROLASES AND ANTI-MICROORGANISM DRUGS AND USES THEREOF
#126NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS
#127NANOPARTICLES FOR PREVENTING PERI/POST-MENOPAUSAL BONE LOSS AND/OR OBESITY
#128COSMETIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS
#129COMPOSITIONS AND METHODS OF USING TWO-PROMOTER VECTOR FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS
#130COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF POMPE DISEASE
#131COMPOSITIONS AND METHODS FOR TREATING SIALIDOSIS
#132THERAPEUTIC REGIMEN FOR THE TREATMENT OF FABRY USING STABILIZED ALPHA-GALACTOSIDASE
#133COMPOSITIONS COMPRISING ACID ALPHA GLUCOSIDASE AND METHODS OF USE THEREOF
#134Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration
#135COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES AND CONDITIONS INCLUDING ECZEMA
#136Hyaluronidase Enzyme Formulations for High Volume Administration
#137Hyaluronidase Enzyme Formulations for High Volume Administration
#138Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#139METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE
#140BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE
#141CIRCULAR RNA VACCINES AND METHODS OF USE THEREOF
#142CRISPR-MEDIATED HUMAN GENOME EDITING WITH VECTORS
#143Lipid Nanoparticle Compositions and Methods for mRNA Delivery
#144LYOPHILIZED FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A
#145ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION
#146TARGETED DELIVERY OF MODIFIED RNA
#147Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#148PARTICLES AND SUSPENSIONS COMPRISING HYALURONAN DEGRADING AGENTS AND METHODS OF USE THEREOF
#149METHOD FOR PROVIDING RELIEF FROM FRUCTAN OR FRUCTOSE INDUCED ABDOMINAL DISCOMFORT
#150AAV-BASED MODULATION OF GBA1 AND RELATED COMPOSITIONS AND USES THEREOF
#151GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD
#152DEVELOPMENT OF AMYLOGLUCOSIDASE AS A MEDICINAL FOOD OR DIETARY SUPPLEMENT
#153COMBINATION THERAPIES INCLUDING PARP1 INHIBITORS
#154RECOMBINANT AAV FOR THE GENE THERAPY OF FABRY DISEASE
#155Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
#156USE OF LYSIN TO RESTORE/AUGMENT ANTIBACTERIAL ACTIVITY IN THE PRESENCE OF PULMONARY SURFACTANT OF ANTIBIOTICS INHIBITED THEREBY
#157METHODS OF TREATING TUMORS
#158Recombinant Human Acid Alpha-Glucosidase
#159PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#160METHODS FOR TREATING BULLOUS PEMPHIGOID USING FCRN ANTAGONISTS
#161Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
#162VSV/NDV HYBRID VIRUSES FOR ONCOLYTIC THERAPY OF CANCER
#163SEMAGLUTIDE SOLUBLE MICRONEEDLE COMPOSITION AND PREPARATION METHOD THEREFOR
#164hypoallergenic milk with immune enhancing function and preparation method thereof
#165ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE
#166ENHANCING ABSORPTION OF DIETARY COMPOUNDS TO PROMOTE HEALTH
#167Human alpha-galactosidase variants
#168Cell wall hydrolases targeting c. acnes
#169CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS
#170DEVICES AND METHODS FOR THE PREPARATION OF A NUTRITIONAL FORMULA
#171THERAPEUTIC AGENT FOR DISC HERNIATION
#172BACILLUS VELEZENSIS COMPOSITIONS AND METHODS OF USE THEREOF
#173Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies
#174SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND BEHAVIOUR IMPAIRMENTS
#175PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG
#176ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS
#177SPHERICAL AGGLOMERATION OF PROTEINS
#178IONIZABLE CATIONIC LIPIDS
#179USE OF LOW pH ACTIVE ALPHA-1,4;/1,6-GLYCOSIDE HYDROLASES (GLCH) AS A FEED ADDITIVE FOR RUMINANTS TO ENHANCE STARCH DIGESTION
#180A PRODUCTION OF A PURIFIED MODIFIED BACTERIAL HYALURONIDASE POLYPEPTIDE, PHARMACEUTICAL COMPOSITIONS AND THEIR USES
#181HYALURONIDASE POLYPEPTIDE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF A NEURODEGENERATIVE DISEASE
#182METHODS AND COMPOSITIONS FOR INCREASING N-ACETYLGLUCOSAMINIDASE ACTIVITY IN THE CNS
#183COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE
#184Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle
#185CLINICAL FORMULATIONS OF ANTI-TIGIT ANTIBODIES
#186VECTOR FOR CANCER TREATMENT
#187SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND BEHAVIOUR IMPAIRMENTS
#188STABLE GEL FORMULATIONS FOR THE TREATMENT OF ACNE VULGARIS
#189FULL LIGHT REPAIR
#190Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
#191GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD
#192ENGINEERED AMYLASE VARIANTS
#193IONIZABLE CATIONIC LIPIDS
#194FUNGAL ENZYME MIXTURES AND USES THEREOF
#195COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MUSHROOM EXTRACT OR POWDER
#196NOVEL RECOMBINANT EXOSOME CONTAINING HYALURONIDASE AND USE THEREOF
#197METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
#198SUBCUTANEOUS UNIT DOSAGE FORMS
#199Microbial Lysozyme for use in the Treatment of Irritable Bowel Syndrome or Inflammatory Bowel Disease
#200GLYCOSIDE HYDOLASES AND THEIR USE IN PREVENTING AND/OR TREATING A PATHOGENIC INFECTION IN AN ANIMAL
#201COMPOSITIONS AND METHODS FOR TREATMENT OF GAUCHER DISEASE
#202Pharmaceutical Composition for Improving and Treating Leukotrichia and/or Alopecia and Preparation Method Thereof
#203Antimicrobial hevamine A-related compositions and methods
#204PH20 polypeptide variants, formulations and uses thereof
#205METHODS FOR PREVENTING CARDIAC OR SKELETAL DEFECTS IN DISEASES INCLUDING MUCOPOLYSACCHARIDOSES
#206PROTEIN CONTAINING BIO-ACTIVE COMPOSITIONS COMPRISING CELLULOSE MICROPARTICLE CARRIERS
#207SUBCUTANEOUSLY ADMINISTERED ANTIBODY-DRUG CONJUGATES FOR USE IN CANCER TREATMENT
#208AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I
#209USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY
#210VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER
#211Chimeric endolysin polypeptide, cluster 3b
#212NOVEL SIALIDASES AND USES THEREOF
#213COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES
#214SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS
#215GNE AS A THERAPEUTIC AGENT
#216Chimeric endolysin polypeptide
#217COMPOUNDS, DEVICES, AND USES THEREOF
#218DEVICE AND METHODS FOR ACNE THERAPEUTICS: ANTIBACTERIAL BACTERIOPHAGES AND ENGINEERED LYSINS
#219Pharmaceutical Composition for Treatment of Mucopolysaccharidosis Type 1
#220SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#221Hyaluronidase Enzyme Formulations for High Volume Administration
#222METHODS OF TREATING TUMORS
#223Method for Delivering Drug to Muscle
#224METHODS OF TREATING CELIAC DISEASE
#225SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
#226TRANSFERRIN RECEPTOR BINDING PROTEINS
#227CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS
#228PH20 polypeptide variants, formulations and uses thereof
#229GENETICALLY MODIFIED HUMAN CELL LINES AND USES THEREOF
#230Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
#231Hyaluronidase enzyme formulations for high volume administration
#232THERMOPLASTIC BIODEGRADABLE ELASTOMERS AND METHODS OF USE
#233Tissue modifier and uses therefor
#234Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
#235METHODS OF TREATMENT AND DOSING OF NATURAL KILLER CELL COMPOSITIONS
#236INFANT FORMULA
#237ENGINEERING OF DNASE ENZYMES FOR MANUFACTURING AND THERAPY
#238COMPOSITIONS COMPRISING PROPIONIBACTERIUM ACNES BACTERIOPHAGES FOR TREATING ACNE
#239SIALYDASE LINKED HIV ANTIBODIES AND METHODS OF USE
#240AMURINS LYSINS, AND LYSIN-ANTIMICROBIAL PEPTIDE (AMP) CONSTRUCTS ACTIVE AGAINST GRAM-NEGATIVE BACTERIA
#241A GENETICALLY MODIFIED CELL LINE PRODUCING A RECOMBINANT GLYCOPROTEIN HAVING A MANNOSE-TERMINATED N-GLYCAN
#242SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
#243METHOD OF TREATING SCHIZOPHRENIA OR SCHIZOPHRENIFORM DISORDER
#244ANIMAL FEED COMPOSITION AND USE THEREOF
#245COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME
#246GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE
#247COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
#248ANTIBACTERIAL PEPTIDE P104 AND LYSIN LYSP53 WITH BROAD-SPECTRUM LYTIC ACTIVITY, AND APPLICATIONS THEREOF
#249CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS
#250SYSTEMS AND METHODS FOR TREATING CORONAVIRUS
#251Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
#252POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#253Dosing Regimens For The Treatment Of Fabry Disease
#254METHODS FOR REDUCING PATHOGENIC E COLI BY SELECTIVE FEED ADDITIVE INTERVENTION COMPRISING ENZYMES SUCH AS MURAMIDASE
#255VIRAL TREATMENT
#256LIPOSOMES AND ITS USE FOR ENZYME DELIVERY
#257Methods and compositions for improved cognition
#258METHODS FOR IMPROVING PHYSICAL EXERCISE PERFORMANCE
#259MODULATION OF AAV-BASED GENE EXPRESSION
#260Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses
#261METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN
#262Transdermal Double-layer Microneedle Based on Hydrogen Producing Probiotics and Its Preparation Method and Application
#263Protein complex including botulinum toxin translocation domain and endolysin and antibacterial composition including same
#264VARIANT IGF2 CONSTRUCTS
#265Catechol Nanoparticle, Catechol Protein Nanoparticle, and Preparation Method and Use Thereof
#266Compositions and Methods for Altering Tissue Specificity and Improving AAV9-Mediated Gene Transfer
#267CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS
#268WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME
#269FORMULATIONS COMPRISING RECOMBINANT ACID ALPHA-GLUCOSIDASE
#270POLYPEPTIDES FOR TREATMENT OF BACTERIAL INFECTIONS
#271COMPOSITIONS COMPRISING PROPIONIBACTERIUM ACNES BACTERIOPHAGES FOR TREATING ACNE
#272METHODS OF TREATMENT FOR FUNCTIONAL DECLINE IN HIPPOCAMPUS, FOR IMPROVING RECOGNITION MEMORY ACCURACY, AND FOR IMPROVING HIPPOCAMPAL NEURONAL FUNCTION
#273AVIAN FOOD ADDITIVE
#274TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA)
#275STABLE LIQUID DISPERSINB COMPOSITIONS
#276PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN
#277AGENT FOR ACTIVATING A NEURON
#278PH20 polypeptide variants, formulations and uses thereof
#279PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof
#280Engineered amylase variants
#281RECOMBINANT ADENO-ASSOCIATED VIRUSES WITH ENHANCED LIVER TROPISM AND USES THEREOF
#282METHODS OF TREATING TUMORS
#283PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE
#284PH20 polypeptide variants, formulations and uses thereof
#285PERI-ORBITAL FULLNESS ASSESSMENT SCALE AND METHODS OF USE THEREOF
#286MRNA THERAPY FOR POMPE DISEASE
#287PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF
#288PH20 polypeptide variants, formulations and uses thereof
#289Antibody Compositions and Methods of Use Thereof
#290COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE
#291DOSING REGIMEN
#292TREATMENT OR PREVENTION OF A DISEASE OR DISORDER
#293USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE
#294ANTIVIRAL AGENTS
#295Controlled-release and stratified cyclodextrin inclusion complex vehicles
#296TREATMENT OR PREVENTION OF HIV INFECTION
#297Development of amyloglucosidase as a medicinal food or dietary supplement
#298FERMENTED MILK FOR REGULATING GUT HEALTH AND PREPARATION METHOD THEREOF
#299COMBINED THERAPEUTIC USE OF ANTIBODIES AND IMMUNOGLOBULIN G-DEGRADING ENZYMES
#300METAL-ORGANIC FRAMEWORK MEDIATED MACROMOLECULE DELIVERY SYSTEM